Tolerance of Myocardium to Ischemia Injury (TOMIS)
Primary Purpose
Reperfusion Injury, Myocardial Ischemia
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
cardiac surgery scheduled in the morning
cardiac surgery scheduled in the afternoon
Sponsored by
About this trial
This is an interventional basic science trial for Reperfusion Injury
Eligibility Criteria
Inclusion Criteria:
- Patient scheduled for coronary artery bypass graft surgery and/or aortic valve replacement with extra-corporeal circulation
- Patient in sinus rhythm at the time of surgery
- Patient older than 18
- Patient able to understand the information and consent forms
Exclusion Criteria:
- Medical history of type 2 diabetes, atrial fibrillation or use of class III anti-arhythmic drug
- left ventricle ejection fraction < 40%
- Pregnancy
- Patient in emergency condition
Sites / Locations
- Lille University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
morning group
afternoon group
Arm Description
cardiac surgery scheduled in the morning
cardiac surgery scheduled in the afternoon
Outcomes
Primary Outcome Measures
ischemia reperfusion injury in ex vivo conditions
measurement of hs troponin T released by the myocardium samples in the superfusion solution after ex vivo conditions mimicking ischemia-reperfusion
Secondary Outcome Measures
Full Information
NCT ID
NCT02812901
First Posted
June 22, 2016
Last Updated
August 29, 2017
Sponsor
University Hospital, Lille
1. Study Identification
Unique Protocol Identification Number
NCT02812901
Brief Title
Tolerance of Myocardium to Ischemia Injury
Acronym
TOMIS
Official Title
Morning / Afternoon Variation in Myocardial Ischemia Tolerance
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
January 2016 (Actual)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to understand the impact of time-of-the day on human myocardial tolerance to ischemia-reperfusion by exploring atrial myocardium biopsied during cardiac surgery. Patients scheduled for non-urgent cardiac surgery (coronary artery by-pas graft and/or aortic valve replacement) will be assigned to a morning or an afternoon cardiac surgery based on randomization. Myocardial biopsies will be explored in ex vivo conditions mimicking ischemia-reperfusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Reperfusion Injury, Myocardial Ischemia
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
88 (Actual)
8. Arms, Groups, and Interventions
Arm Title
morning group
Arm Type
Other
Arm Description
cardiac surgery scheduled in the morning
Arm Title
afternoon group
Arm Type
Other
Arm Description
cardiac surgery scheduled in the afternoon
Intervention Type
Procedure
Intervention Name(s)
cardiac surgery scheduled in the morning
Intervention Description
cardiac surgery scheduled in the morning
Intervention Type
Procedure
Intervention Name(s)
cardiac surgery scheduled in the afternoon
Intervention Description
cardiac surgery scheduled in the afternoon
Primary Outcome Measure Information:
Title
ischemia reperfusion injury in ex vivo conditions
Description
measurement of hs troponin T released by the myocardium samples in the superfusion solution after ex vivo conditions mimicking ischemia-reperfusion
Time Frame
the day of the myocardial biopsy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient scheduled for coronary artery bypass graft surgery and/or aortic valve replacement with extra-corporeal circulation
Patient in sinus rhythm at the time of surgery
Patient older than 18
Patient able to understand the information and consent forms
Exclusion Criteria:
Medical history of type 2 diabetes, atrial fibrillation or use of class III anti-arhythmic drug
left ventricle ejection fraction < 40%
Pregnancy
Patient in emergency condition
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Montaigne, MD, PhD
Organizational Affiliation
Lille University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lille University Hospital
City
Lille
ZIP/Postal Code
59000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29107324
Citation
Montaigne D, Marechal X, Modine T, Coisne A, Mouton S, Fayad G, Ninni S, Klein C, Ortmans S, Seunes C, Potelle C, Berthier A, Gheeraert C, Piveteau C, Deprez R, Eeckhoute J, Duez H, Lacroix D, Deprez B, Jegou B, Koussa M, Edme JL, Lefebvre P, Staels B. Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet. 2018 Jan 6;391(10115):59-69. doi: 10.1016/S0140-6736(17)32132-3. Epub 2017 Oct 26.
Results Reference
derived
Learn more about this trial
Tolerance of Myocardium to Ischemia Injury
We'll reach out to this number within 24 hrs